Our Experts Working With Your Experts
Next Generation Molecular Method Development
MR DNA scientists have over 20 years of continuous experience (not combined experience) developing new and novel molecular methods. Systematics, microsatellite screening, MHC assays, viral assays, protozoan assays and more. Our team’s goal is to take advantage of each new technology as it arrives and leverage unique properties to develop unique, improved and more cost effective molecular methods and tools.
Put MR DNA on your team
This initiative is one component of the MR DNA program and constitutes a major NIH effort to broaden access to rapid assay technologies. This program will fund the development and adaptation of biological assays for use in automated high throughput molecular screening (HTS). It is intended that this Initiative promote the development of automated screening projects. High throughput molecular screening (HTS) is the automated, simultaneous testing of thousands of distinct molecular signatures in models of biological mechanisms. Active compounds identified through HTS can provide the starting point in the design of powerful research tools that allow pharmacological probing of basic biological mechanisms, and which can be used to establish the role of a molecular target in a disease process, or, its ability to alter the metabolism or toxicity of a therapeutic. The immense potential of HTS to impact our understanding of biological mechanisms is largely untapped because access to automated screening facilities and large compound libraries is limited in academic, government and non-profit research sectors.
Many in vitro biological models are currently used to study biological pathways, the effects of genetic perturbations and to establish a disease association. These can be adapted to high throughput formats for the purpose of screening large collections of biologically active compounds. There are a number of characteristics that make an assay suitable for high throughput approaches. The assay must be robust, reproducible and have a readout that is amenable to automated analysis. In addition, it must be possible to miniaturize the assay, for example; to a 96-well plate (or higher density) format or flow-cytometric approach. Further, the assay protocol should be simple enough for automated handling. A broad range of models share many of these features, including; biochemical assays, cellular models and certain model organisms such as yeast or C. elegans. This initiative will support the development of innovative assays for use in both basic research and in therapeutics development programs, with an emphasis on novelty of assay approach and/or novel targets and mechanisms.
- Bacterial detection and identification
- MHC characterization
- cSNP indel assays
- Viral and fungal assays
- Genome comparison
- Target enrichment sequencing
- Quantitative and expression assays
- Short Read Long Read
- Highly multiplexed assays
- Bioinformatics development
- Screening and development